Aya Mohamed, Medical Oncologist, Associate Lecturer of Medical Oncology, Member of ASCO, shared on X:
“Small Cell Transformation in EGFR Mutant NSCLC: JTO & JTO CRR
EP-Based Combinations Improve PFS, While DLL3 Expression in 87.5% of Tumors Positions DLL3 Targeted Therapy as a Promising Future Strategy.”
Title: EGFR-Mutant Non-Small-Cell Lung Cancer with Small Cell Transformation: Clinicopathological Features, Treatment Landscape, and Biomarker Profiles
Authors: Chi-Lu Chiang, Ying-Ting Liao, Yi-Chen Yeh, Ruei-Lin Sun, Hsu-Ching Huang, Yung-Hung Luo, Chia-I Shen, Heng-Sheng Chao, Yen-Han Tseng, Tsu-Hui Shiao, Ruihong Wang, Haitao Wang, David S. Schrump, Yuh-Min Chen
Read the full article.
Other articles featuring Aya Mohamed on OncoDaily.